<DOC>
	<DOCNO>NCT01179529</DOCNO>
	<brief_summary>This study aim evaluate therapeutic potential omalizumab atopic dermatitis , work biomarkers predictive treatment response .</brief_summary>
	<brief_title>Atopic Dermatitis Biomarker Identification Trial Omalizumab Usage</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Age ≥ 1870 year age , body weight ≥ 20 kg ≤ 150 kg Dermatological diagnosis AD , SCORAD &gt; =20 A positive RAST ( ≥CAP1 ) result least one aeroallergen specific IgE total IgE &gt; =100kU/l screening ( within previous 12 month ) Eligible receive systemic therapy AD accordance local guideline Signed informed consent patient Evidence skin disease AD ( e.g . psoriasis ) inclusion time Treatment systemic AD medication investigational drug within 30day washout period Concomitant treatment substance interfere immune system Permanent severe disease , especially affect immune system , except asthma Pregnancy breast feed History food drug relate severe anaphylactoid anaphylactic reaction ( ) History presence epilepsy , significant neurological disorder , cerebrovascular attack ischemia History presence myocardial infarction cardiac arrhythmia require drug therapy Elevated serum IgE level reason allergy and/or urticaria ( e.g . : parasite infection , hyperimmunoglobulin E syndrome , Wiskott Aldrich syndrome clinical allergic bronchopulmonary aspergillosis ) Evidence severe renal dysfunction significant hepatic disease Evidence active infection opinion investigator would compromise patient 's ability tolerate therapy History malignancy organ system , treat untreated , whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin Clinically significant laboratory abnormality ( associate AD ) Visit 1 Known hypersensitivity ingredient , include excipients ( sucrose , histidine , polysorbate 20 ) study medication drug relate Omalizumab ( e.g . : monoclonal antibody , polyclonal gammaglobulin ) Patients consider potentially unreliable envisage patient may consistently attend schedule study visit Patients serious psychiatric and/or psychological disturbance Patients history drug alcohol abuse Patients unable complete patient diary complete questionnaire paper Patients condition prior/current treatment , opinion investigator render patient ineligible study schedule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Atopic dermatitis ( atopic eczema )</keyword>
</DOC>